Top Page
WELL Health Technologies Corp
(TSX:WELL)
WELL Health Technologies Corp (WELL) vs. iShares MSCI Canada ETF (EWC)
WELL Health Technologies Corp Business Overview & Revenue Model
WELL Health Technologies Corp Earnings Call Summary
WELL Health Technologies Corp Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 982.26M | 919.69M | 776.05M | 569.14M | 302.32M | 50.24M |
| Gross Profit | 360.96M | 363.01M | 372.27M | 303.29M | 153.69M | 21.22M |
| EBITDA | -48.66M | 122.52M | 101.88M | 95.99M | 21.27M | -495.00K |
| Net Income | -29.05M | 32.61M | 82.00K | 19.07M | -30.69M | -2.62M |
Balance Sheet | ||||||
| Total Assets | 1.81B | 1.81B | 1.41B | 1.32B | 1.26B | 262.73M |
| Cash, Cash Equivalents and Short-Term Investments | 103.16M | 131.67M | 43.42M | 48.91M | 61.92M | 86.89M |
| Total Debt | 474.24M | 425.09M | 426.28M | 358.42M | 401.94M | 23.57M |
| Total Liabilities | 900.98M | 877.55M | 563.16M | 503.78M | 554.37M | 43.75M |
| Stockholders Equity | 834.43M | 867.61M | 767.67M | 732.34M | 618.24M | 217.37M |
Cash Flow | ||||||
| Free Cash Flow | -10.20M | -6.70M | 37.20M | 70.14M | 19.59M | -6.52M |
| Operating Cash Flow | 9.86M | 9.52M | 66.44M | 76.55M | 22.27M | -5.38M |
| Investing Cash Flow | -103.44M | -60.23M | -106.42M | -37.93M | -499.78M | -44.21M |
| Financing Cash Flow | 142.54M | 133.50M | 10.63M | -52.85M | 452.53M | 120.84M |
WELL Health Technologies Corp Technical Analysis
WELL Health Technologies Corp Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $309.61M | 2.42 | 33.87% | 2.21% | -29.54% | 667.77% | |
70 Outperform | C$23.40M | 20.30 | 4.53% | ― | 4.09% | ― | |
66 Neutral | C$1.22B | 30.45 | -3.53% | ― | 17.19% | -191.01% | |
62 Neutral | C$1.63B | ― | -3.31% | 1.22% | 9.88% | 11.07% | |
61 Neutral | C$186.99M | ― | -4.48% | ― | -0.69% | 8.08% | |
52 Neutral | $7.53B | 0.20 | -61.87% | 2.28% | 16.72% | 1.10% |
WELL Health Technologies Corp Corporate Events
WELL Health Technologies Corp has announced an update on its Canadian Clinics business, reflecting improved financial guidance and an expanded credit facility. The company is ahead of internal expectations, forecasting over $450 million in revenue and over $60 million in Adjusted EBITDA for fiscal 2025. This growth is driven by both organic expansion and strategic acquisitions, including two new clinics in British Columbia, contributing significantly to the company’s revenue and operational scale. Additionally, WELL has extended its credit facility to $200 million, supporting further expansion and cost optimization initiatives aimed at enhancing efficiency and operational excellence across its Canadian clinics.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp announced the successful election of its directors during the annual general meeting held on June 30, 2025. The voting results showed strong support for the nominees, with a significant portion of the company’s common shares voted by proxy. This outcome reinforces WELL Health’s governance and strategic direction, potentially strengthening its position in the digital healthcare industry.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp. has announced a significant expansion in primary care capacity, adding over 45,000 new patient openings across its national clinic network in Ontario, Alberta, and Manitoba. This expansion is facilitated by investments in physician recruitment, including internationally trained doctors, and the implementation of advanced digital workflows and automation infrastructure. These efforts aim to address Canada’s access-to-care crisis by combining physician recruitment with digital health solutions to enhance care capacity and improve patient outcomes.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$7.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
CRH Medical Corporation, a subsidiary of WELL Health Technologies Corp, has partnered with WovenX Health to enhance gastrointestinal (GI) care access and streamline delivery. This strategic collaboration combines CRH’s GI solutions with WovenX’s virtual platform to improve patient access, operational efficiency, and care standards, offering a consumer-centric model that addresses long-standing barriers in the GI community.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp. has appointed Ric Leong as its Chief Accounting Officer to lead the company’s accounting operations and financial planning as it continues to grow through acquisitions. Leong, with a strong background in financial leadership from his previous roles at Hootsuite and Avigilon, will focus on strengthening WELL’s financial reporting and integration processes, enhancing financial planning and analysis capabilities, and supporting the company’s expansive acquisition strategy.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp announced that its subsidiaries, Intrahealth, Pentavere, and OceanMD, have been selected for Canada Health Infoway’s 2025 Vendor Innovation Program. This recognition highlights the company’s leadership in the digital health sector, as their projects aim to enhance data quality, care coordination, and access to health information, thereby advancing interoperability in Canada’s healthcare system.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp. has entered into an automatic share purchase plan (ASPP) with a broker to facilitate the repurchase of its common shares under a previously announced normal course issuer bid (NCIB). This move allows the company to buy back up to 6,326,417 common shares, representing approximately 2.5% of its outstanding shares, during a 12-month period. The ASPP enables the broker to purchase shares even during periods when WELL is restricted from trading due to insider trading rules or internal blackout periods. This strategic initiative is expected to enhance shareholder value and reflects WELL’s confidence in its business prospects.
The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.
WELL Health Technologies Corp announced its financial results for Q4 and the full year 2024, reporting a record annual revenue of $919.7 million, a 19% increase from the previous year. Despite challenges such as deferred revenue from Circle Medical and impacts from a cyberattack on Change Healthcare, the company achieved significant growth in patient visits and Canadian operations. WELL Health projects a positive outlook for 2025, with expected revenue between $1.40 billion to $1.45 billion and Adjusted EBITDA ranging from $190 million to $210 million, driven by strong organic growth and strategic initiatives.